Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Doxorubicin hydrochloride (HB4183)
Description:Antibiotic. DNA topisomerase II inhibitor. Apoptosis inducer.
Purity:>99%
Doxycycline hyclate (HB4608)
Description:Broad-spectrum antibiotic. Used in inducible Tet-on/ Tet-off gene expression systems for gene editing.
Purity:>95%
Epirubicin hydrochloride (HB4187)
Description:DNA synthesis and function inhibitor. Inhbits DNA topoisomerase II
Purity:>98%
Eremofortin B (HB3892)
Description:Eremophilane sesquiterpene. Nontoxic secondary metabolite from Penicillium roqueforti.
Purity:>98%
FK 506 (HB0289)
Description:Potent calcineurin phosphatase 2B inhibitor. Enhances osteoblastic differentiation in mesenchymal cells.
Purity:>99%
FTY720 hydrochloride (HB3899)
Description:Sphingosine 1-phosphate (S1P) receptor (S1P1, S1P3, S1P4, and S1P5) modulator
Purity:>98%